| scholarly article | Q13442814 |
| P2093 | author name string | I E M Bultink | |
| M W P Tsang-A-Sjoe | |||
| P2860 | cites work | Survival in systemic lupus erythematosus, 1995-2010. A prospective study in a Danish community | Q22299249 |
| Neutrophils in the pathogenesis and manifestations of SLE | Q27000384 | ||
| mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging | Q28081442 | ||
| The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study | Q28212163 | ||
| Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry | Q30582614 | ||
| Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort | Q30655475 | ||
| Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | Q31107094 | ||
| The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide | Q33401164 | ||
| Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort | Q33455990 | ||
| Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. | Q33529416 | ||
| Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study | Q33561291 | ||
| Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus | Q33664831 | ||
| Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus | Q33664993 | ||
| Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies | Q34131724 | ||
| Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy | Q34162386 | ||
| Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus | Q34162739 | ||
| Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. | Q34760339 | ||
| Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis | Q34975939 | ||
| Lupus erythematosus with leflunomide: induction or reactivation? | Q35554724 | ||
| Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice | Q35642120 | ||
| Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus | Q35879759 | ||
| Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study | Q35927877 | ||
| Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting | Q35941075 | ||
| Antimalarials may influence the risk of malignancy in systemic lupus erythematosus | Q35953395 | ||
| N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial | Q36139749 | ||
| Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus | Q36220831 | ||
| Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals | Q36246086 | ||
| Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus | Q36277899 | ||
| Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis | Q36302245 | ||
| Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort | Q36434629 | ||
| Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis | Q36681801 | ||
| Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 | ||
| Prednisone, lupus activity, and permanent organ damage | Q36761678 | ||
| Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers | Q36843689 | ||
| Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy | Q37146440 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus | Q37582300 | ||
| Autophagy as a target for anticancer therapy | Q37876679 | ||
| Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus | Q37884880 | ||
| The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science | Q38066667 | ||
| The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus | Q38099256 | ||
| Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis | Q38173894 | ||
| Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy | Q38176594 | ||
| Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study | Q38372154 | ||
| Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study | Q38466691 | ||
| Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines | Q39577031 | ||
| Low plasma androgens in women with systemic lupus erythematosus | Q41331741 | ||
| Methotrexate use in systemic lupus erythematosus. | Q41491179 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort | Q41917167 | ||
| Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. | Q41919391 | ||
| Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. | Q41919852 | ||
| Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. | Q41919912 | ||
| The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy | Q41920001 | ||
| A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group | Q41926859 | ||
| Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). | Q41927831 | ||
| Predictors of survival in Chinese patients with lupus nephritis | Q41929732 | ||
| Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus | Q41930370 | ||
| Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). | Q41931965 | ||
| On the inhibitory effect of chloroquine on blood platelet aggregation | Q41935192 | ||
| Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus | Q41944460 | ||
| Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. | Q42956224 | ||
| Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial | Q43205821 | ||
| Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial | Q43255461 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study | Q43692733 | ||
| Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide | Q43993205 | ||
| Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). | Q44316147 | ||
| Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus | Q45088819 | ||
| The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. | Q45821336 | ||
| The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy | Q46146983 | ||
| Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort | Q46194226 | ||
| Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial | Q46227344 | ||
| Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study | Q46484874 | ||
| Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. | Q46573574 | ||
| Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients | Q46613737 | ||
| Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy | Q46622469 | ||
| Hydroxychloroquine: the cornerstone of lupus therapy | Q46643929 | ||
| Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis | Q46749401 | ||
| Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis | Q46818795 | ||
| Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus | Q46864446 | ||
| The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus | Q50502906 | ||
| Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. | Q53649024 | ||
| Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. | Q53850772 | ||
| Systemic lupus erythematosus | Q55933861 | ||
| Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus | Q57332373 | ||
| A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years | Q57753805 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| lupus erythematosus | Q188297 | ||
| P304 | page(s) | 2793-2806 | |
| P577 | publication date | 2015-10-19 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Systemic lupus erythematosus: review of synthetic drugs | |
| P478 | volume | 16 |
| Q55314394 | Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis. |
| Q47822363 | Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients. |
| Q58098750 | Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review |
| Q38806513 | Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies |
| Q64227620 | Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis |
| Q36265699 | Individualized patient decision-aid for immunosuppressive drugs in women with lupus nephritis: study protocol of a randomized, controlled trial |
| Q36766244 | Progressive Multifocal Leukoencephalopathy and Systemic Lupus Erythematosus: Focus on Etiology |
| Q37511805 | The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation |
| Q37593731 | The soluble cytoplasmic tail of CD45 (ct-CD45) in human plasma contributes to keep T cells in a quiescent state |
Search more.